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1597Heart failure (HF) is among the most common causes of
morbidity and mortality in the Western world. Regardless of
the underlying cause, HF patients show a hyperactive sympa-
thetic nervous system with elevated plasma catecholamine levels
and long-term activation of the beta-adrenergic receptor (b-AR)
signaling pathway. This leads to desensitization and attenuated
b-AR responsiveness due to decreased b1-AR number and
function (1,2). These changesmay participate in the progression
of HF by further compromising contractile performance.
On the other hand, some of the functional abnormalities of
failing cardiomyocytes, particularly b-AR desensitization, may
also be adaptations that protect from detrimental effects of
long-term b-AR stimulation, for example, arrhythmias and
myocardial hypertrophy (2). Accordingly, drugs intended to
reverse or bypass b-AR desensitization (catecholamines or
phosphodiesterase [PDE] inhibitors), cause symptomatic
improvement in the short term, but demonstrate long-term
increased mortality due to sudden cardiac death (3).
Conversely, large-scale clinical trials have shown that b-AR
blockers reduce mortality in HF (4–6).
See page 1607
There is recent evidence that higher myocardial levels of
the second messenger cyclic guanosine monophosphate
(cGMP) may be beneﬁcial, partly by antagonizing the cyclic
adenosine monophosphate (cAMP)-mediated effects of
b-AR overstimulation (7–9). Cyclic GMP is synthesized by
either soluble guanylyl cyclases activated by nitric oxide
(NO) or particulate guanylyl cyclases activated by the
natriuretic peptides atrial natriuretic peptide (ANP) and
B-type natriuretic peptide (BNP) (10). In the heart, cAMP
and cGMP levels are regulated in a highly speciﬁc and
stimulus-dependent manner by cyclic nucleotide degrading
PDEs (11,12). Among the PDE superfamily, the PDE2
isoform is unique in being activated by cGMP via binding to
the regulatory N-terminal GAF-B domain (13,14). cGMP
functions as an allosteric regulator of PDE2, and occupancy
of this binding site changes the kinetics for cyclic nucleotide
hydrolysis, stimulating the hydrolysis of cAMP 5- to 30-
fold. This may provide a negative cross-talk mechanism
between cAMP and cGMP signaling pathways. Indeed, we
showed previously that cGMP activation of PDE2 locally
depletes cAMP in the vicinity of L-type Ca2þ channels, thus
strongly antagonizing b-AR or cAMP stimulation of the
L-type Ca2þ current (ICa,L) (15–17). In the human atrium,
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accepted May 6, 2013.PDE2 activity controls basal
ICa,L (18), and activation of this
PDE2 by cGMP also decreases
stimulated ICa,L (19). In neonatal
cardiomyocytes, local PDE2 is
coupled to a b-AR–stimulated
pool of adenylyl cyclases and
cAMP-dependent protein kinase
type-II isoforms, antagonizing
b-AR inotropic responses partly
via the b3-AR/NO/cGMP axis
(9,20).
However, despite the unique
function of PDE2 in cGMP and
cAMP signaling, and the well-
known perturbations in b-AR
and NO/natriuretic peptide sig-
naling pathways, it is unknown
whether PDE2 has a signiﬁcant
pathophysiological role in failing
hearts. Here, we show that myo-
cardial PDE2 is markedly up-
regulated in HF and that speciﬁc
PDE2 inhibition restores b-AR
responsiveness in diseased cardio-
myocytes, whereas PDE2 over-
expression blunts catecholamine
responsiveness and protects
against pathological hypertrophy. These data establish PDE2
as a new member of the group of proteins contributing to the
well-known phenomenon of b-AR desensitization in chronic
HF and implicates PDE2 as a key downstream element that
might be a target for the development of novel antiadrenergic
therapeutic approaches.Methods
The study conformed to the principles outlined in the
Declaration of Helsinki, and all procedures were approved
by the ethics committees of our institutions. Patient char-
acteristics and drugs, as well as all methods used, including
preparation of protein extracts, PDE activity assays, myocyte
isolation, and adenoviral transductions, cAMP measure-
ments by ﬂuorescence resonance energy transfer (FRET),
Ca2þ transients and cell shortening (IonOptix, Milton,
Massachusetts), ICa,L measurements, and data analysis and
statistics are detailed in the supplemental methods section in
the Online Appendix.Results
Myocardial PDE2 is increased in end-stage HF. We
measured PDE2 protein levels in left ventricular (LV)
myocardium from patients with terminal HF (ejection
fraction 37%) and compared them with nonfailing donor
hearts (n ¼ 6). Each sample was normalized to calsequestrin
Figure 1 PDE2 Is Up-Regulated in Failing Hearts
(A) Phosphodiesterase-2 (PDE2) protein levels in left ventricular (LV) myocardium from patients with end-stage dilated cardiomyopathy (DCM) or ischemic cardiomyopathy (ICM),
or aortic stenosis (AS) with myocardial hypertrophy but preserved cardiac function compared to nonfailing donor hearts (NF); n ¼ 5 to 6. (B) PDE2 protein levels in LV
myocardium from dogs subjected to rapid pacing–induced heart failure (HF) compared with Sham-operated controls (Sham); n ¼ 7 to 9. PDE2 expression was normalized to
calsequestrin (CSQ). *p < 0.05 versus NF or Sham, and #p ¼ 0.05 versus NF. rel. ¼ relative.
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1598as an internal control. Immunoblots demonstrated greater
signal intensity in the failing hearts (w2-fold) with dilated
(n ¼ 5) and ischemic (n ¼ 5) cardiomyopathy (Fig. 1A; see
Online Table 1 for patient characteristics). This was inde-
pendent of b-blocker treatment before heart transplantation
(Online Fig. 1). The protein data were conﬁrmed at a func-
tional level by a radioenzymatic assay in the presence and
absence of the speciﬁc PDE2 inhibitor BAY 60-7550 (BAY
Cayman Chemical Company, Ann Arbor, Michigan) (100
nmol/l) showing about a 2-fold greater PDE2 activity toward
cAMP in failing hearts compared with nonfailing donor heart
controls (Online Fig. 2). Interestingly, PDE2 expression did
not differ between nonfailing controls and hypertrophied LV
myocardium from patients with preserved cardiac function
(ejection fraction 50%) who underwent aortic valve
replacement due to aortic stenosis (n ¼ 6) (Fig. 1A, Online
Table 1). Given the well-known limitations of human heart
tissue samples, including partly uncontrolled clinical param-
eters, we re-evaluated PDE2 expression in a well-established
large-animal HF model of dogs subjected to ventriculartachycardia pacing (n ¼ 9). Immunoblotting conﬁrmed our
ﬁndings in human HF showing w2-fold greater PDE2
protein expression in failing dog hearts compared with sham
controls (n ¼ 7) (Fig. 1B).
Increased myocardial PDE2 expression/activity results
from excessive adrenergic drive in vivo. We tested whether
PDE2 up-regulation is like b1-AR down-regulation a conse-
quence of pathological b-AR overstimulation. As expected,
long-term isoprenaline (ISO, Sigma-Aldrich (Saint Quentin,
France)) infusion (2.4 mg/g/day for 4 days) in rats induced
cardiac hypertrophy (as indicated by an increased heart-to-
body weight ratio) (Fig. 2A) and induction of the fetal gene
expression program (as indicated by a >8-fold increase in
transcript levels of the cardiac fetal gene ANP) (Fig. 2B). In
line with our hypothesis, this was accompanied by anw2-fold
increase in PDE2 protein levels (Fig. 2C). Next, we deter-
mined PDE2 mRNA levels by quantitative reverse-
transcription polymerase chain reaction and found 4-fold
higher levels in the ISO-infused hearts compared
with control hearts, indicating that PDE2 is regulated at the
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Figure 2 PDE2 in a Rat Model of Long-Term ISO Exposure: Elevated Expression and Activity
Male Wistar rats were either treated with isoprenaline (ISO) (2.4 mg/g/day) or vehicle (0.9% NaCl) for 4 days. ISO-mediated induction of cardiac hypertrophy was analyzed by
determining (A) heart-weight to body-weight ratio (HW/BW); n ¼ 14, and (B) LV atrial natriuretic peptide (ANP) mRNA levels normalized to glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH); n ¼ 4 to 6. (C) Representative immunoblot and quantiﬁcation of PDE2 protein expression in LV homogenate. Values are normalized to CSQ; n ¼ 8. (D) LV
PDE2 mRNA levels normalized to CSQ; n ¼ 5 to 6. (E and F) PDE2 activity in LV tissue toward cyclic adenosine monophosphate (cAMP)/cyclic guanosine monophosphate
(cGMP) was measured by radioenzymatic assay and deﬁned as the fraction of total cAMP/cGMP-PDE activity inhibited by 100 nmol/l BAY 60-7550 (BAY); n ¼ 6. *p < 0.05 and
#p ¼ 0.06 versus Vehicle. Abbreviations as in Figure 1.
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1599transcriptional level (Fig. 2D).To determine whether the
increased LV PDE2 protein expression is translated into
greater activity, we analyzed PDE2-dependent cAMP and
cGMP hydrolytic activities. As shown in Figures 2E and 2F,
relative cAMP-PDE2 activity was w4-fold higher andcGMP-PDE2 activity was w2-fold greater in LV homoge-
nates from the ISO- versus vehicle-treated hearts.
Higher cAMP-PDE2 hydrolytic activity in diseased cardio-
myocytes. To further evaluate changes in PDE2 at
the cardiomyocyte level, ventricular cardiomyocytes were
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Figure 3 Higher PDE2 cAMP Hydrolytic Activity in Hypertrophied and b-Adrenergically Desensitized Cardiomyocytes
After 4 days ISO or NaCl treatment, cardiomyocytes were isolated from the sacriﬁced animals and transduced for 48 h with recombinant adenovirus encoding the cAMP sensor
Epac2-camps. Adult rat ventricular myocytes were stimulated with the indicated substances and cyan ﬂuorescent protein (CFP)/yellow ﬂuorescent protein (YFP) ratio was
determined upon 436-nm excitation (emission ﬁlters: YFP 535  15 nm, CFP 480  20 nm). (A) Average of the responsiveness to 1 nmol/l ISO as percentage of maximal
response (forskolin þ IBMX). (B) Fluorescence resonance energy transfer (FRET) traces presented as CFP/YFP ratio of cardiomyocytes treated with 100 nmol/l BAY, 100 mmol/l
IBMX, and 10 mmol/l forskolin. (C) Percentage of maximal (forskolin þ IBMX) response; NaCl n ¼ 7, ISO n ¼ 11. (D) Representative traces normalized to basal CFP/YFP ratio of
cardiomyocytes treated with 100 nmol/l ISO and 50 mmol/l sodium nitroprusside (SNP). (E) Percentage of maximal (ISO) response; NaCl n ¼ 7, ISO n ¼ 7. *p < 0.05 versus
NaCl. Abbreviations as in Figures 1 and 2.
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1600isolated from adult rats either subjected to long-term ISO or
vehicle infusion, and cAMP-PDE2 hydrolytic activity was
monitored using the adenovirally expressed exchange protein
directly activated by cAMP– cAMP sensor (Epac2-camps)
FRET biosensor for cAMP. Acute application of ISO
(1 nmol/l) produced a clear increase in cAMP in controlcardiomyocytes, which was markedly attenuated in car-
diomyocytes from ISO-treated hearts (70%) (Fig. 3A), as
expected from the known b-AR desensitization in this model.
The basal FRET ratios were lower in cells isolated from ISO-
treated rats (Fig. 3B). Application of BAY had no signiﬁcant
effect on cAMP accumulation in control cardiomyocytes, in
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Figure 4
PDE2 Inhibition Increases b-AR Stimulation of
Ca2þ Transients and Sarcomere Shortening in
Hypertrophied and b-Adrenergically Desensitized
Cardiomyocytes
Ventricular cardiomyocytes were isolated from adult rat hearts subjected to either
long-term ISO or NaCl. (A) Representative traces of Ca2þ transients (top) and
sarcomere shortening (bottom) recorded in cardiomyocytes paced at 0.5 Hz and
loaded with Fura-2 AM (5 mmol/l) showing the effect of a b-adrenergic receptor
(b-AR) stimulation with 1 nmol/l ISO, and of PDE2 inhibition by BAY (100 nmol/l)
on top of ISO. (B) Mean absolute values of Fura-2 ratio (upper graphs) and
sarcomere shortening (lower graphs) in control conditions, or in the presence of
ISO or ISO þ BAY (n ¼ 15 to 18). xp < 0.05 versus control (Con); $p < 0.05
versus ISO; *p < 0.05 versus NaCl. Abbreviations as in Figures 2 and 3.
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1601line with the fact that PDE2 accounts for only 3% of the total
cAMP-hydrolyzing activity under normal conditions (20). By
comparison, application of the nonselective PDE inhibitor 3-
isobutyl-1-methylxanthine (IBMX, Sigma-Aldrich [Saint
Quentin, France]) (100 mmol/l) or the adenylyl cyclase-activator
forskolin (10 mmol/l) in the continued presence of BAY
produced a similar net increase in cAMP (Fig. 3B). The
absolute cAMP levels (cyan ﬂuorescent protein/yellow ﬂuo-
rescent protein ratio in Fig. 3B) were lower in ISO car-
diomyocytes versus control (p ¼ 0.05). However, in long-term
ISO–treated cardiomyocytes, application of BAY alone
produced a signiﬁcant increase in cAMP levels (Figs. 3B and
3C). The overall maximal changes in cAMP levels from basal
to forskolin/IBMX maximum were similar in both groups,
suggesting comparable rates of cAMP production. These data
indicate a stronger contribution of PDE2 to cAMP hydrolysis
in diseased cardiomyocytes.
Because PDE2 is activated by cGMP, we tested whether
higher PDE2 activity in diseased cardiomyocytes could be
further enhanced by cGMP synthesis. To this end, we
challenged cardiomyocytes with the NO donor sodium
nitroprusside (SNP Sigma-Aldrich, Munich, Germany) (50
mmol/l) after acute b-AR stimulation with ISO. SNP
reduced the ISO response in long-term ISO cardiomyocytes,
but had no signiﬁcant effect in vehicle controls (Figs. 3D
and 3E). Therefore, further activation of up-regulated
PDE2 is still possible in diseased cardiomyocytes. Interest-
ingly, these data point to a predominant effect of the
cGMP-induced PDE2 activation over the cGMP-mediated
PDE3 inhibition in disease.
To investigate how increased PDE2 expression trans-
lates into function, Ca2þ transients (Fura-2 ratio) and
sarcomere shortening were measured in isolated car-
diomyocytes with the IonOptix system. ISO (1 nmol/l)
produced a large increase in the Fura-2 ratio and sarcomere
shortening in NaCl myocytes, but only a modest increase in
cardiomyocytes from ISO-treated hearts (Fig. 4), again
conﬁrming the b-AR desensitization. BAY alone produced
a small but signiﬁcant effect on both parameters in vehicle-
treated cardiomyocytes (Online Table 2). However, in
long-term ISO–treated cardiomyocytes, BAY produced
a 2-fold larger effect (Online Table 2). Importantly, the
application of BAY in addition to ISO had no signiﬁcant
effect on vehicle-treated cardiomyocytes, but increased 2-
to 3-fold the ISO effect on Ca2þ transients and sarcomere
shortening in the long-term ISO group (Fig. 4B). Thus,
PDE2 inhibition partially restores b-AR responsiveness,
which indicates that PDE2 is in fact playing a functional
role in diseased myocytes.
Overexpression of PDE2 blunts responses to acute b-AR
stimulation and protects from norepinephrine-induced
hypertrophy. To dissect further the speciﬁc role of up-
regulated PDE2, we infected adult rat ventricular myocytes
with either an adenovirus encoding hemagglutinin-tagged
mouse PDE2A2 (Ad-PDE2) or a control adenovirus
encoding b-galactosidase (Ad-bGal) or green ﬂuorescent
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Figure 5 PDE2 Overexpression Decreases b-AR Stimulation of ICa,L in Cardiomyocytes
The whole-cell conﬁguration of the patch-clamp technique was used to record the L-type Ca2þ current (ICa,L). The cells were depolarized every 8 s from 50 to 0 mV during 400
ms. The use of 50 mV as the holding potential allowed the inactivation of voltage-dependent Naþ currents. Kþ currents were blocked by replacing all Kþ ions with external and
internal Csþ. (A and B) Representative examples of individual ICa,L current traces showing the effect of ISO (100 nmol/l, 15 s) alone (A) or in the presence of the PDE2 inhibitor
BAY (100 nmol/l) (B) on ICa,L in adult rat ventricular myocytes infected with either adenovirus encoding b-galactosidase (Ad-bGal) (top traces) or Ad-PDE2 (bottom traces). To
correct for differences in cell size, the current traces were normalized to cell membrane capacitance and are presented as current densities in pA/pF. (C) Normalized average
time course of ICa,L amplitude following ISO pulse stimulation (100 nmol/l, 15s) in each group; n ¼ 7 to 8. (D) Effect of ISO (100 nmol/l, 15 s) in the presence of BAY (n ¼ 5).
Abbreviations as in Figures 1 to 4.
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1602protein (EGFP). Immunoblot detection of overexpressed
PDE2 and, at the functional level, higher PDE2 hydrolysis
activity toward cAMP and cGMP in Ad-PDE2–infected
cardiomyocytes are shown in Online Fig. 3. We then
determined the consequences for cAMP changes in response
to b-AR stimulation. For this, cardiomyocytes coexpressing
Epac2-camps and either b-Gal or PDE2 were challenged
with a short application of ISO (100 nmol/l, 15 s) either
alone or in the presence of BAY (100 nmol/l). As monitored
by FRET, PDE2 overexpression markedly decreased intra-
cellular cAMP levels generated by b-AR stimulation. This
b-AR response was almost completely restored when the
cardiomyocytes were additionally challenged with BAY
(Online Fig. 4).
Next, we examined whether PDE2 overexpressionmodiﬁes
the b-AR regulation of excitation–contraction coupling.Although overexpression of PDE2 had no signiﬁcant effect
on basal ICa,L density (4.8 0.7 pA/pF inAd-PDE2, n¼ 7 vs.
3.2  0.7 pA/pF in Ad-bGal, n ¼ 8), the response to a pulse
application of 100 nmol/l ISO was markedly blunted in
myocytes infected with Ad-PDE2 (Figs. 5A and 5C).
However, inhibition of PDE2 with BAY restored a normal
response to ISO (Figs. 5B and 5D). In another series of
experiments, sarcomere shortening and the Fura-2 ratio were
simultaneously recorded (Fig. 6A).Under basal conditions, the
amplitude and relaxation kinetics of sarcomere shortening
were not signiﬁcantly different between Ad-bGal and Ad-
PDE2 cardiomyocytes (Figs. 6B and 6C). Ad-PDE2 car-
diomyocytes developed signiﬁcantly smaller Ca2þ transients
thanAd-bGal, yetwithno difference in the relaxation kinetics.
When the cells were challengedwith ISO (1nmol/l), Ad-bGal
cardiomyocytes responded with a strong increase in both
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Figure 6 PDE2 Overexpression Blunts b-AR Stimulation of Ca2þ Transients and Sarcomere Shortening in Cardiomyocytes
Adult rat ventricular myocytes were loaded with Fura-2 and stimulated at a frequency of 0.5 Hz. Sarcomere length and Fura-2 ratio were recorded using an IonOptix System. (A)
Representative traces of basal and ISO (1 nmol/l) stimulated Ca2þ transient and sarcomere shortening in Ad-bGal and Ad-PDE2–infected cells. (B) Average amplitudes of Ca2þ
transients and sarcomere shortening. (C) Maximal rates of relaxation and Ca2þ reuptake; n ¼ 8 to 11; xp < 0.05 versus basal; zp ¼ 0.05 versus basal; *p < 0.05 versus
Ad-bGal; #p ¼ 0.05 versus Ad-bGal. Abbreviations as in Figures 1, 2, 4, and 5.
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1603contraction and Ca2þ transient amplitudes (Fig. 6B), accom-
panied by an acceleration in their relaxation kinetics (Fig. 6C).
In PDE2-overexpressing cardiomyocytes, however, these
responses were markedly attenuated. To test sarcoplasmic
reticulum function at the molecular level, we assayedphosphorylated phospholamban (P-PLB). Immunoblots
showed that overexpression of PDE2 does not change the
phosphorylation level of PLB under basal conditions, but
signiﬁcantly decreases the P-PLB/total PLB ratio after stim-
ulation with 1 nmol/l ISO (Online Fig. 5). These results
Mehel et al. JACC Vol. 62, No. 17, 2013
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1604suggest that PDE2overexpressiondoes not affect sarcoplasmic
reticulum function under basal conditions and is consis-
tent with our ﬁndings that the b-AR response of Ca2þ tran-
sients and sarcomere shortening was inhibited by
PDE2 overexpression without any negative effect on
basal contractility. Collectively, our ﬁndings highlight a direct
and potent involvement of PDE2 in b-AR responsiveness in
HF.
Cardiac hypertrophy is 1 of the ﬁrst stages of stress-
induced HF. To examine the effect of up-regulated PDE2
on cardiomyocyte hypertrophy, we determined the increase
in cell size in cultured adult cardiomyocytes in response to
24-h stimulation with norepinephrine or phenylephrine. As
shown in Figure 7, PDE2 overexpression attenuated signif-
icantly the norepinephrine- and phenylephrine-induced
increase in cell surface area. These data indicate that PDE2
has protective effects under conditions of a- and/or b-AR–
induced pathological hypertrophy.
Discussion
The major ﬁndings of the present study are: 1) myocardial
PDE2 is up-regulated in human and experimental HF; 2)
speciﬁc PDE2 inhibition restores b-AR responsiveness in
diseased cardiomyocytes; 3) increased PDE2 activity is
further enhanced by cGMP stimulation via NO donors; and
4) PDE2 overexpression abolishes b-AR responsiveness
without affecting basal contractility and protects against
pathological hypertrophy.
PDE2 is up-regulated in failing hearts. Consistent with
the literature, our study shows rather low protein expression of
PDE2 in healthy hearts (Fig. 1), and accordingly, inhibition of
PDE2 has little effect on cAMP hydrolytic activity in healthyBasal NOR PHE
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Figure 7
PDE2 Overexpression Protects Cardiomyocytes
Against Hypertrophy Induced by a/b-AR Stimulation
Cardiomyocytes were stimulated with 10 mmol/l norepinephrine (NOR) or 10
mmol/l phenylephrine (PHE) for 24 h, and the cellular surface area was determined
by microscopy; n ¼ 5 to 6 preparations. xp < 0.05 versus basal; *p < 0.05
adenovirus encoding enhanced green ﬂuorescent protein (Ad-EGFP) versus
Ad-PDE2.cardiomyocytes (Figs. 3B and 3C).However, our data indicate
that in HF, with enhanced adrenergic drive and marked
perturbations in the b-AR and NO/natriuretic peptide
signaling, PDE2 becomes up-regulated and, by mediating
cGMP-dependent cAMP degradation, contributes to the
imbalance between these 2 signaling pathways. This is
consistent with recent ﬁndings showing disorganization of
cAMP-dependent protein kinase (PKA) regulatory subunits
and A-kinase anchoring proteins, which showed increased
capturing of cGMP-dependent protein kinase (PKG) and
PDE2 (21). By contrast, the expression and activity of other
cAMP-hydrolyzing PDEs (e.g., PDE3) is reduced in human
and experimental HF (22,23). PDE regulation in vivo is
complex, and 1 transduction signal may affect several PDEs
differently. For instance, cGMP activates PDE2, but
competitively inhibits PDE3 (24). Through the latter
mechanism, an increase in cGMP levels inhibits cAMP
degradation. Thus, it is likely that under HF conditions, both
the lower PDE3 and higher PDE2 activity could be a conse-
quence of increased cGMP signaling that is further ampliﬁed
by increased PDE2 and/or reduced PDE3 expression. In this
context, it is interesting to note that the cGMP-hydrolyzing
PDE5 is also increased in failing human hearts (8). This
may partly compensate for the PDE2/PDE3 alterations.
b-AR signaling is a biologically dynamic system that
adapts quickly and reversibly by desensitization in response
to overstimulation. Accordingly, b-blockers “resensitize”
the failing heart and are associated with normalization of
b-ARs (1,2). However, b-blocker therapy did not appear to
normalize up-regulated myocardial PDE2 expression in our
samples, pointing to different regulatory mechanisms of
altered b-ARs and PDE2 in HF. In addition, it was
intriguing to observe that PDE2 expression was still normal
in LV tissue samples from aortic stenosis patients with
myocardial hypertrophy and preserved cardiac function
(Fig. 1A). This indicates an important role for PDE2 in
decompensated rather than earlier stages of myocardial
remodeling.
PDE2 up-regulation and its consequences after long-
term excessive b-AR drive. The long-term ISO infusion
model recapitulates key features of human HF, particularly
pathological hypertrophy and the well-known phenomenon
of b-AR desensitization (25,26). In this model, we observed
an increase in PDE2 protein expression, mRNA transcrip-
tion, and PDE2 cGMP/cAMP hydrolytic activity. Speciﬁc
PDE2 inhibition partially restored b-AR responsiveness in
diseased cardiomyocytes, indicating that PDE2 up-regulation
contributes signiﬁcantly to the well-known phenomenon of
b-AR desensitization, considered to be a major protective
mechanism in HF. A central translational question is whether
potentially beneﬁcial PDE2 up-regulation in HF can be
further ampliﬁed by coactivation of cGMP synthesis. Indeed,
diseased cardiomyocytes showed a signiﬁcant decrease in
cAMP levels when challenged with the NO donor SNP,
further validating the feasibility of PDE2 activation in the
context of HF (see the following text).
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1605PDE2 abolishes b-AR–mediated inotropic effects via
cAMP degradation and reduction of ICa,L amplitude. In
cardiomyocytes isolated from long-term ISO rats, b-AR
stimulation of cell shortening and Ca2þ transients was
severely blunted due to PDE2 overexpression. Moreover,
adenoviral PDE2 overexpression markedly blunts ISO-
induced inotropy, cAMP generation, and the increase in
ICa,L and Ca
2þ transients in adult cardiomyocytes. Im-
portantly, all effects were reversible upon speciﬁc PDE2
inhibition with BAY. This is the ﬁrst direct evidence that
PDE2 overexpression inhibits the increase in ICa,L by
reducing cAMP concentrations and indicates that PDE2
regulates a speciﬁc cAMP pool that modulates b-AR
signaling. Our ﬁndings are consistent with previous reports
showing indirectly that activation of PDE2 is responsible for
the inhibitory effect of intracellular cGMP on ICa,L in frog
ventricular (16,27) and human atrial myocytes (19) and that,
via stimulation of soluble guanylyl cyclase with NO donors,
attenuates b-AR stimulation in frog (27) and neonatal rat
cardiomyocytes (20).
PDE2 does not affect basal contractility but protects
against pathological hypertrophy. NO/natriuretic peptides
have been shown to exert both beneﬁcial cGMP-dependent
antihypertrophic and potentially detrimental negative
inotropic effects on the failing heart. Both effects have been
largely attributed to activation of cGMP-dependent PKG
(28,29), with uncertain contribution of cGMP-dependent
PDE2 activation. Our ﬁndings in PDE2-overexpressing
cardiomyocytes suggest no negative effect on basal contrac-
tility or ICa,L (Figs. 5B and 6B), but beneﬁcial effects of
PDE2 up-regulation in the context of pathological hyper-
trophy induced by norepinephrine and phenylephrine
(Fig. 7). The antihypertrophic properties together with the
maintained basal contractility suggest that the up-regulated
PDE2 in HF is beneﬁcial despite limiting the contractile
reserve upon b-AR stimulation, a proﬁle that is quite similar
to b1-AR down-regulation in HF.
Potential limitations. To study PDE function, we evalu-
ated different species, including humans. However, the
role played by each PDE isoform varies among mammalian
species (11,12), and accordingly, our results may not reca-
pitulate the situation in humans in all details. In addition,
selective PDE2 inhibitors or activators for in vivo use have
not been developed, and PDE2 knockout mice have not yet
been generated to study the precise role of PDE2 in the
healthy and diseased heart. Therefore, we studied the func-
tion of cardiac PDEs using speciﬁc inhibitors or adenoviral
overexpression in vitro, but this might not reﬂect the com-
plex regulation of the PDEs in vivo, particularly of PDE2,
which is a dual esterase that is positively regulated by cGMP.
Novelty and clinical signiﬁcance. The current therapeutic
strategies for HF are complex and only moderately efﬁcient.
Clearly, improved HF therapies are necessary, but a lack
of understanding of the pathophysiological mechanisms
underlying HF has hindered the development of more
effective, rational therapeutic approaches. Several studiesdemonstrated beneﬁcial effects of cGMP stimulation in HF,
and multicenter trials are currently testing the therapeutic
value of inhibition of cGMP hydrolyzing PDEs (PDE5) or
activation of soluble guanylyl cyclase in patient populations
(30). The rationale of these studies is consistent with our
hypothesis that augmentation of cGMPsignalingmay serve as
a myocardial brake, blunting the detrimental effects of exces-
sive catecholamines in HF. Despite substantial advances in
the ﬁeld, there are still controversies regarding the therapeutic
value of activated cGMP signaling via PDE5 inhibition, and
the clinical translation of increasing cGMP synthesis
has been limited by hypotension and tolerance development
with nitrates and rather neutral responses to natriuretic
peptides (30).
Conclusions
To the best of our knowledge, this study is ﬁrst to show that
PDE2 is up-regulated in HF and constrains the effects of
long-term b-AR stimulation on cardiomyocyte Ca2þ
handling and contractility in HF. Moreover, the up-
regulated PDE2 expression appears unaffected by b-
blocker therapy, but could be further enhanced in diseased
cardiomyocytes and protects against hypertrophic stimuli
without negatively affecting basal contractility, clearly sug-
gesting that activation of PDE2 could be a novel and feasible
approach for the treatment of HF. In addition, cAMP
hydrolysis through PDE2 has been shown to mediate the
ANP/cGMP-induced decreases of aldosterone production
in adrenal glomerulosa cells, suggesting synergistic beneﬁcial
effects on the cardiorenal axis (31). Overall, our data suggest
that increased myocardial PDE2 levels may constitute an
important defense mechanism in end-stage HF by antago-
nizing b-AR/cAMP–mediated cardiac toxicity. Thus, aug-
menting myocardial PDE2 activity in early stages of HF
may represent a new subcellular antiadrenergic therapeutic
strategy in HF. Further extensive studies in large-animal
HF, as well as the development of speciﬁc PDE2 activa-
tors for in vivo use, is required to deﬁne precisely the speciﬁc
contributions of PDE2 to HF pathophysiology and to
validate the therapeutic value of enhanced PDE2 activity in
HF patients.
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APPENDIX
For supplemental ﬁgures and tables, and an expanded Methods section,
please see the online version of this paper.
